News Details Page

Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced that it has entered

Automating Wilson Wolf's G-Rex® bioreactors with Multiply Labs' robotic technology is driven by a mutual goal to standardize, simplify, and reduce costs for cell and gene-modified therapy manufacturing a robotics company developing industry-leading automated manufacturing